Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced  positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer.

The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile.

Key findings include:

·      Stable disease observed in >30% of evaluable patients

·      Prolonged treatment duration includes one patient extending beyond 16 months.

·      35% of patients remain on therapy and follow up

·      Favorable safety and tolerability profile consistent with prior reports